ATE394104T1 - Adenosin a2a rezeptor-antagonisten zur behandlung und vorbeugung von leberfibrose, zirrhose und fettleber - Google Patents

Adenosin a2a rezeptor-antagonisten zur behandlung und vorbeugung von leberfibrose, zirrhose und fettleber

Info

Publication number
ATE394104T1
ATE394104T1 AT01910529T AT01910529T ATE394104T1 AT E394104 T1 ATE394104 T1 AT E394104T1 AT 01910529 T AT01910529 T AT 01910529T AT 01910529 T AT01910529 T AT 01910529T AT E394104 T1 ATE394104 T1 AT E394104T1
Authority
AT
Austria
Prior art keywords
cirrhosis
liver
adenosin
prevention
treatment
Prior art date
Application number
AT01910529T
Other languages
German (de)
English (en)
Inventor
Bruce Cronstein
Edwin Chan
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Application granted granted Critical
Publication of ATE394104T1 publication Critical patent/ATE394104T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT01910529T 2000-02-10 2001-02-12 Adenosin a2a rezeptor-antagonisten zur behandlung und vorbeugung von leberfibrose, zirrhose und fettleber ATE394104T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18154600P 2000-02-10 2000-02-10

Publications (1)

Publication Number Publication Date
ATE394104T1 true ATE394104T1 (de) 2008-05-15

Family

ID=22664744

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01910529T ATE394104T1 (de) 2000-02-10 2001-02-12 Adenosin a2a rezeptor-antagonisten zur behandlung und vorbeugung von leberfibrose, zirrhose und fettleber

Country Status (11)

Country Link
US (1) US6555545B2 (OSRAM)
EP (1) EP1272897B1 (OSRAM)
JP (1) JP2004502640A (OSRAM)
AT (1) ATE394104T1 (OSRAM)
AU (2) AU2001238124B2 (OSRAM)
CA (1) CA2398908C (OSRAM)
DE (1) DE60133887D1 (OSRAM)
DK (1) DK1272897T3 (OSRAM)
ES (1) ES2307593T3 (OSRAM)
PT (1) PT1272897E (OSRAM)
WO (1) WO2001058241A2 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6196459B1 (en) * 1998-05-11 2001-03-06 Ubiq Incorporated Smart card personalization in a multistation environment
WO2003080649A2 (en) * 2002-03-20 2003-10-02 Regents Of The University Of Minnesota Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
ITRM20070088A1 (it) * 2007-02-19 2008-08-20 Francesco Fringuelli Composti derivati della colchicina, procedimento per la loro preparazione e usi in campo medico.
WO2009023179A2 (en) * 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
EP2217233B1 (en) * 2007-10-26 2018-08-08 New York University School of Medicine Methods and compositions for treating hepatic diseases
KR101516677B1 (ko) * 2008-01-31 2015-05-04 고토부키 세이야쿠 가부시키가이샤 지방성 간 질환의 치료용 의약 조성물
US8536306B2 (en) 2008-10-01 2013-09-17 The Scripps Research Institute Human A2A adenosine receptor crystals and uses thereof
US20100204265A1 (en) * 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
BRPI1009398A2 (pt) 2009-03-13 2016-03-08 Advinus Therapeutics Private Ltd compostos de pirimidina fundida substituída
WO2010106145A1 (en) * 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oxidated derivatives of triazolypurines useful as ligands of the adenosine a2a receptor and their use as medicaments
US8796290B2 (en) 2009-11-09 2014-08-05 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
SG183146A1 (en) 2010-02-05 2012-09-27 Heptares Therapeutics Ltd 1,2,4-triazine-4-amine derivatives
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
CN110809577A (zh) 2017-06-30 2020-02-18 雷沃医疗有限公司 腺苷a2a受体的调节剂
CA3086282A1 (en) 2017-12-19 2019-06-27 Impetis Biosciences Ltd. Pharmaceutical composition for the treatment of cancer
EP3735413B1 (en) 2018-01-04 2022-07-06 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof
WO2020128036A1 (en) 2018-12-21 2020-06-25 Ryvu Therapeutics S.A. Modulators of the adenosine a2a receptor
WO2025018901A1 (en) 2023-07-17 2025-01-23 Ryvu Therapeutics S.A. Modulators of the adenosine a2a and a2b receptor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705658A (en) 1986-04-07 1987-11-10 Capsule Technology International, Ltd. Method for drying gelatin in the manufacture of hard shell gelatin capsules
US5063233A (en) 1986-11-14 1991-11-05 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives useful as adenosine receptor agonists
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US5036381A (en) 1990-06-15 1991-07-30 Motorola, Inc. Multiple electronic devices within a single carrier structure
GB2264948B (en) 1992-03-13 1996-10-16 Merck & Co Inc Human adenosine receptors
US5426101A (en) 1992-09-30 1995-06-20 Merrell Dow Pharmaceuticals Inc. 2-substituted adenosines with A-2 receptor affinity
AU6516494A (en) 1993-04-15 1994-11-08 New York University Adenosine receptor agonists for the promotion of wound healing
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US5859019A (en) 1997-03-07 1999-01-12 Trustees Of The University Of Pennsylvania Methods for protecting against cardiac ischemia by administering adenosine A2a receptor antagonists
AU750322B2 (en) 1997-05-09 2002-07-18 Trustees Of The University Of Pennsylvania, The Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
AU7449598A (en) * 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response

Also Published As

Publication number Publication date
US6555545B2 (en) 2003-04-29
EP1272897A2 (en) 2003-01-08
WO2001058241A9 (en) 2002-10-17
AU2001238124B2 (en) 2006-05-25
DK1272897T3 (da) 2008-09-15
ES2307593T3 (es) 2008-12-01
WO2001058241A2 (en) 2001-08-16
CA2398908A1 (en) 2001-08-16
CA2398908C (en) 2009-12-15
JP2004502640A (ja) 2004-01-29
EP1272897B1 (en) 2008-05-07
DE60133887D1 (de) 2008-06-19
AU3812401A (en) 2001-08-20
US20020002145A1 (en) 2002-01-03
PT1272897E (pt) 2008-08-18

Similar Documents

Publication Publication Date Title
ATE394104T1 (de) Adenosin a2a rezeptor-antagonisten zur behandlung und vorbeugung von leberfibrose, zirrhose und fettleber
DE602004028841D1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
WO2005027895A3 (en) Thyroid hormone analogs and methods of use in angiogenesis
DZ2618A1 (fr) Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie.
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE60127277D1 (de) Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
SG155054A1 (en) Human anti- neutralizing antibodies as selective pathway inhibitors
ATE210449T1 (de) Verfahren und zusammensetzung zur verminderung von reperfusionsschäden des myokards
EP1505990A4 (en) METHOD FOR THE TREATMENT OF HEPATITIS
DE69932510D1 (de) Vaskularisierungsinhibitoren
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
ATE506959T1 (de) Verwendung von il-18 inhibitoren
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
WO2008043107A3 (en) Use of tight junction antagonists to treat inflammatory bowel disease
JP2004502640A5 (OSRAM)
DE60124387D1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
ID24184A (id) Obat untuk perawatan disfungsi ereksi
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
TNSN03065A1 (en) BIOPESTICIDE COMPOSITIONS
ATE199641T1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
WO2002015664A3 (en) Methods of preventing or treating west nile virus and other infections
NO20051261L (no) Morfin-6-glukuronidsalt
EA200700979A1 (ru) Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272897

Country of ref document: EP

REN Ceased due to non-payment of the annual fee